- Home
- SISI vs ANNX Comparison
SISI vs ANNX Comparison
Compare SISI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- ANNX
- Stock Information
- Founded
- SISI 1997
- ANNX 2011
- Country
- SISI China
- ANNX United States
- Employees
- SISI N/A
- ANNX N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- ANNX Health Care
- Exchange
- SISI Nasdaq
- ANNX Nasdaq
- Market Cap
- SISI 227.4M
- ANNX 253.8M
- IPO Year
- SISI 2016
- ANNX 2020
- Fundamental
- Price
- SISI $5.05
- ANNX $2.17
- Analyst Decision
- SISI
- ANNX Strong Buy
- Analyst Count
- SISI 0
- ANNX 5
- Target Price
- SISI N/A
- ANNX $13.00
- AVG Volume (30 Days)
- SISI 1.6M
- ANNX 1.3M
- Earning Date
- SISI 09-29-2025
- ANNX 08-14-2025
- Dividend Yield
- SISI N/A
- ANNX N/A
- EPS Growth
- SISI N/A
- ANNX N/A
- EPS
- SISI N/A
- ANNX N/A
- Revenue
- SISI $9,601,324.00
- ANNX N/A
- Revenue This Year
- SISI N/A
- ANNX N/A
- Revenue Next Year
- SISI N/A
- ANNX N/A
- P/E Ratio
- SISI N/A
- ANNX N/A
- Revenue Growth
- SISI 1133.26
- ANNX N/A
- 52 Week Low
- SISI $4.71
- ANNX $1.29
- 52 Week High
- SISI $664.80
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- SISI 38.19
- ANNX 45.44
- Support Level
- SISI $5.82
- ANNX $2.03
- Resistance Level
- SISI $6.00
- ANNX $2.36
- Average True Range (ATR)
- SISI 0.66
- ANNX 0.14
- MACD
- SISI 0.13
- ANNX -0.00
- Stochastic Oscillator
- SISI 6.10
- ANNX 26.07
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.